Cell and Gene Therapy: Key Considerations for Employers with U.S.-based Populations

As more cell and gene therapies (CGTs) come to market, they have the potential to improve patient care and outcomes. Yet their associated clinical complexity and high cost require employers and their health plans to take a closer look at how these therapies are being accessed and administered.